Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Animal models for complement deficiencies

M M Frank1

  • 1Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA.

Journal of Clinical Immunology
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement activation.

Immunology today·2014
Same author

Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.

Gene therapy·2008
Same author

Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies.

Molecular therapy : the journal of the American Society of Gene Therapy·2004
Same author

Complement activation influences Staphylococcus aureus adherence to endothelial cells.

Infection and immunity·2003
Same author

Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis.

Infection and immunity·2003
Same author

Complement 1 inhibitor is a regulator of the alternative complement pathway.

The Journal of experimental medicine·2001
Same journal

Facial Dysmorphism and Severe Vascular Phenotype in TRNT1 Deficiency with Concomitant Antithrombin III Deficiency.

Journal of clinical immunology·2026
Same journal

Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.

Journal of clinical immunology·2026
Same journal

Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.

Journal of clinical immunology·2026
Same journal

Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center.

Journal of clinical immunology·2026
Same journal

Correction to: Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis.

Journal of clinical immunology·2026
Same journal

Hypoproteinemia and Hypogammaglobulinemia Due to a Homozygous FCGRT Mutation.

Journal of clinical immunology·2026
See all related articles

Animal models are crucial for understanding complement-mediated diseases and autoimmunity. New genetic and molecular techniques are expanding the range of available models, offering better insights into complement system functions and therapeutic strategies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • The complement system is vital for host defense and implicated in autoimmune diseases.
  • Traditional animal models (genetic deficiency, complement inactivation) offer partial insights but have limitations.
  • Limited availability and scope of existing genetic deficiency models hinder research.

Purpose of the Study:

  • To review existing and emerging animal models for studying complement-mediated diseases.
  • To highlight advancements in genetic engineering and molecular biology for creating novel complement models.
  • To emphasize the potential of these models in understanding human complement-related pathologies.

Main Methods:

  • Review of established animal models with complement deficiencies (guinea pig, dog, rabbit, rat, mouse, pig).

Related Experiment Videos

  • Discussion of complement-inactivating agents, including cobra venom factor and intravenous immune globulin.
  • Exploration of new molecular biology techniques for generating gene knockout and transgenic complement models.

    • Main Results:

    • Several genetic deficiency models exist but are often understudied.
    • Cobra venom factor is widely used but has limitations due to antigenicity.
    • Intravenous immune globulin shows promise for complement inhibition.
    • Gene knockout mice (C3, Factor B) and transgenic animals (CR1) represent significant advancements.

    Conclusions:

    • New molecular and genetic approaches are rapidly expanding the toolkit for complement research.
    • Advanced models, including transgenic animals expressing complement regulatory proteins, hold great promise for studying xenograft transplantation and other diseases.
    • These evolving animal models are essential for advancing our understanding of complement's role in human health and disease.